Arch Therapeutics, Inc. (OTCQB: ARTH) is a medical device company offering an innovative therapeutic approach to “stasis and barrier applications.” This means improved time to cessation of bleeding (hemostasis) and the control of fluid leakage (sealant) during surgery and trauma care. Arch intends to transform the landscape of interventional healthcare with novel products to seal and protect tissue. Arch’s flagship product known as the AC5 Surgical Hemostatic Device™ is designed to elegantly achieve hemostasis in minimally invasive (laparoscopic) and open surgical procedures. In preclinical tests, AC5™ has been found to be simple, effective, and versatile.
If successful, the AC5 Surgical Hemostatic Device™ could make surgery faster and safer. This means better surgical outcomes for potentially everyone, including you.
CEO Terrence Norchi, MD - Presents a corporate overview at The LD Micro Invitational in Los Angeles at The Luxe Sunset Bel Air Hotel on Wednesday, June 4 at 9:30 AM PT. - Click here to register for the live audio and HD video webcast. - which will be archived for 90 days post event.